Skip to content

Neuropace, Inc. NPCE Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

LivaNova logo
LivaNovaLIVN
$2.73M-32.3%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$582K+41.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$338K+5.0%
ITG
Integer HoldingsITGR
$2.45M-0.1%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s non-cash lease expense?
Neuropace, Inc. (NPCE) reported non-cash lease expense of $453K in Q1 2026.
How has Neuropace, Inc.'s non-cash lease expense changed year-over-year?
Neuropace, Inc.'s non-cash lease expense increased by 9.7% year-over-year, from $413K to $453K.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.